A pharmacogenetic approach to the treatment of patients with PPARG mutations

Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and severe metabolic disease in many cases. Missense mutations in PPARG are present in ~1:500 people. Whilst mutations are often binarily classified as ‘benign’ or ‘deleterious’, prospective functional classifica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes
Main Authors: Agostini, Maura, Schoenmakers, Erik, Beig, Junaid, Fairall, Louise, Szatmari, Istvan, Rajanayagam, Odelia, Muskett, Fred, Adams, Claire, Marais, A. David, O’Rahilly, Stephen, Semple, Robert K., Nagy, Laszlo, Majithia, Amit R., Schwabe, John, Blom, Dirk J., Murphy, Rinki, Chatterjee, Krishna, Savage, David B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5967605/
https://ncbi.nlm.nih.gov/pubmed/29622583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db17-1236
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados